Sep 04, 2020 The US Food and Drug Administration has issued a warning letter to Mylan Laboratories Limited's plant in Telangana for significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). USFDA in their letter dated…

Recent Post
- CDSCO Introduces Online Process for Additional Variant Applications in Cosmetics
- India Imposes National Ban on Nimesulide for Veterinary Use Due to Toxicity Risks
- Major Relief for MSME Pharma Manufacturers: MoHFW Extends Deadline for Revised GMP Compliance
- Pharmacovigilance system compliance in India
- Simplifying Clinical Trial Amendment Approvals in India